nivolumab

Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,

Abstract

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).

Org: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, The First People's Hospital of Foshan,

Abstract

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.

Org: Bristol Myers Squibb, Cancer Research SA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institut Paoli-Calmettes, Marseille, France, Instituto Catalán de Oncología,

Abstract

Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.

Org: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, University Hospital Zurich, Zürich, Switzerland, CEPCM, Dermatology and Skin Cancer Department, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France, Linear Clinical Research, Nedlands, Western Australia, Australia, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,

Abstract

BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.

Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,

Abstract

A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).

Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,

Abstract

Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.

Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,

Abstract

Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).

Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Georgetown-Lombardi Comprehensive Cancer Center, Bristol Myers Squibb, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,

Abstract

Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.

Org: Bristol Myers Squibb, Oncosite Centro de Pesquisa Clínica em Oncologia, Puerta de Hierro University Hospital, Madrid, Spain, Dana-Farber Cancer Institute, Boston, MA, USA, McGill University Health Centre, Montreal, QC, Canada,

Abstract

Multicenter randomized phase II study of short course FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA).

Org: Omaha, NE, NewYork-Presbyterian/Weill Cornell Medicine, UNMC,

Abstract

Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.

Org: MetroHealth Cancer Center, University of Wisconsin Madison, Cleveland VA,

Abstract

A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.

Org: Columbia University Irving Medical Center, New York, NY, USA, Dana-Farber Cancer Institute, Miami Cancer Institute, Baptist Health South Florida, Rhode Island Hospital,

Abstract

IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.

Org: Department of Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Florida Cancer Specialists & Research Institute, Sarah Cannon Research Institute and Sidney Kimmel Cancer Center, Thomas Jefferson University,

Abstract

Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.

Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,

Abstract

ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort—A GEIS, ISG and UCL study.

Org: University College London Hospital NHS Trust and Great Ormond Street Hospital, Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM), IRCCS Istituto Ortopedico Rizzoli, Hospital Universitario Miguel Servet,

Abstract

A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.

Org: Institute Gustave Roussy and Paris Saclay University, Dermatology Department Hospital Center University De Lille, Department of Dermatology Comprehensive Cancer Center, Westdeutsches Tumorzentrum University Hospital Essen & Research Alliance Ruhr & Research Center One Health University Duisburg-Essen, Department of Medical Oncology Dana-Farber Cancer Institute,

Abstract

Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.

Org: Horizon Oncology Research LLC, University of Utah Health, The University of Sydney Medical School, BioAtla Inc.,

Abstract

First-line osemitamab (TST001) plus nivolumab and capox for advanced g/GEJ cancer (TranStar102): Results of cohort G from a phase I/IIa study.

Org: Fujian Cancer Hospital, Fuzhou, China, Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China, Department of Gastrointestinal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Central Hospital Affiliated to Shandong First Medical University; Jinan Central Hospital, Shandong University, Jinan, China, Affiliated Hospital Zhejiang University, Hangzhou, China,

Abstract

A phase I trial on the intra- and post-operative intracranial administration of ipilimumab and nivolumab in patients with recurrent high-grade glioma.

Org: Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), CellCarta,

Abstract

Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.

Org: Compugen Ltd., Compugen USA Inc.,

Abstract

Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma.

Org: Department of Gastroenterology, Hepatology, and Nutrition University of Texas MD Anderson Cancer Center,

Abstract

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).

Org: Gustave Roussy Cancer Campus, EORTC Headquarters, Université Clermont Auvergne, Dermato-Oncology and CIC AP-HP Hôpital Saint Louis, Université de Versailles-Saint Quentin en Yvelines,

Abstract

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.

Org: Medical University of Gdańsk, Gdańsk, Poland, International Centre for Thoracic Cancers (CICT), Gustave Roussy Cancer Center, Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine,

Abstract

Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702—Survival results.

Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Breast Cancer Trials - Australia and New Zealand, NHMRC Clinical Trials Centre, Monash Health, Bentleigh East, VIC, Australia, Macarthur Cancer Therapy Center,

Abstract

Trends in prices of checkpoint inhibitors in the US, 2016-2023.

Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,

Abstract

SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.

Org: The Miriam Hospital,

Abstract

Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).

Org: The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, HCA Healthcare global Sarah Cannon Research Institute, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, University of Chicago, Comprehensive Cancer Center, Chicago, IL, Jefferson Medical College, Philadelphia, PA,

Abstract

International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).

Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,

Abstract

Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649).

Org: OPEN Health,

Abstract

Retrospective study of ivosidenib for patients with recurrent IDH mutant gliomas.

Org: University of Pittsburgh, University of Pittsburgh Cancer Institute, UPMC Cancer Center - Hillman Cancer Center,

Abstract

Early clues in the battle against advanced gastric cancer: How plasma ctDNA signals the effectiveness of PD-1 inhibitors with chemotherapy.

Org: Gastric Cancer Center, The First Affiliated Hospital with Nanjing Medical University,

Abstract

Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immune-related adverse events from immune checkpoint inhibitors.

Org: Department of Haematology Oncology, National University Cancer Institute Singapore, Department of Haematology-Oncology, Rheumatology Division, National University Hospital,

Abstract

Overall survival results from the phase 2 NIVOFGFR2 study of first-line nivolumab plus CAPOX in patients with FGFR2-positive, PD-L1-positive metastatic gastric cancer.

Org: Bureau for Cancer Research - BUCARE, Todua Clinic, Tashkent State Dental Institute,

Abstract

A phase 2 study evaluating response and biomarkers in patients with microsatellite stable (MSS) advanced colorectal cancer (CRC) treated with nivolumab/relatlimab.

Org: Bloomberg-Kimmel Institute for Cancer Immunotherapy,

Abstract

Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.

Org: Wollongong Hospital, Genesis Care, Bowel Health Service,

Abstract

Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Org: Sutter Cancer Research Consortium, City of Hope Chicago,

Abstract

An exploratory study on prediction of risk for abemaciclib-induced interstitial lung disease or hepatotoxicity by specific human leukocyte antigen alleles.

Org: Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, Department of Breast Medical Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan, Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan, Department of Breast Surgery, Kansai Rosai Hospital, Amagasaki, Japan,

Abstract

Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial.

Org: Department of Gastric Surgery, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences,

Abstract

PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.

Org: Department of Interventional Radiology,

Abstract

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.

Org: Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Institute of Cancer of São Paulo, University of São Paulo, Ono Pharmaceutical Company Ltd.,

Clinical trial

The Effectiveness and Safety of Lenvatinib Combined Anti-programmed Death Immunotherapy for the Advanced Hepatocellular Carcinoma

Status: Completed, Estimated PCD: 2021-12-30

Abstract

SOGUG-Vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.

Org: Toledo, Spain, Santiago De Compostela, Spain, Sevilla, Spain, Oviedo, Spain, Huelva, Spain,

Abstract

BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMBhigh cohort.

Org: University of Bonn, University of Frankfurt, University of Würzburg, MVZ für Hämatologie und Onkologie Köln Am Sachsenring GmbH, Hospital Cologne-Merheim,

Abstract

Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.

Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,

Abstract

Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.

Org: Macquarie University, Chris O'Brien Lifehouse, Melanoma Institute Australia, Netherlands Cancer Institute (NKI-AVL),

Abstract

Combining a WT1 cancer vaccine (galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1-expressing diffuse pleural mesothelioma (DPM): A phase I study.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial).

Org: Department of Medical Oncology, Kyoto University Hospital, Kyoto, Japan, Department of Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan, Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan,

Abstract

Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitors by investigation of CD8+ immune infiltrate with [89Zr] crefmirlimab berdoxam PET.

Org: Department of Dermatology, Eberhard Karls University of Tübingen, Department of Dermatology, University Hospital Tuebingen, Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tuebingen,

Abstract

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.

Org: Instituto Oncológico Fundación Arturo López Pérez and Department of Oncology, Instituto Nacional del Cáncer, Santiago, Chile, FAICIC Clinical Research, Veracruz, Mexico, Dermatology, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France,

Abstract

A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.

Org: UPMC Hillman Cancer Center, Pittsburgh, PA, UT Health Science Center at San Antonio, Mays Cancer Center, San Antonio, TX,

Abstract

Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial.

Org: University of Sao Paulo, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center,

Abstract

A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.

Org: Alaska Oncology and Hematology, LLC., Bristol Myers Squibb Research,

Abstract

Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma.

Org: Laura and Isaac Permitter Cancer Center,

Abstract

A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma.

Org: Lehigh Valley Topper Cancer Institute,

Abstract

Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study.

Org: BC Cancer-Vancouver Centre, University of British Columbia,

Abstract

A signal-finding study of nivolumab and relatlimab in patients with advanced chordoma.

Org: Division of Hematology and Oncology, UCLA Department of Medicine, Los Angeles, CA, Division of Hematology and Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Cumming School of Medicine, Department of Surgery, Orthopedic Surgery, Calgary, Department of Orthopedic Surgery, UCLA,

Abstract

FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer.

Org: U.S. Food and Drug Administration, Silver Spring, MD, Office of Oncologic Diseases, Center for Drug Evaluation and Research, Oncology Center of Excellence,

Abstract

Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update.

Org: Netherlands Cancer Institute, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, University Medical Center Utrecht,

Abstract

Cost-effectiveness in perioperative therapy in the era of immune checkpoint inhibitors.

Org: Juntendo University Graduate School of Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine,

Abstract

Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients.

Org: Baylor University Medical Center, Dallas, TX,

Abstract

Overall survival after isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM II trial).

Org: University of Gothenburg, Skane University Hospital Comprehensive Cancer Center, University Hospital of Umeå,

Abstract

Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.

Org: Barts Health NHS Trust Saint Bartholomew’s Hospital,

Abstract

Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.

Org: LungenClinic, Grosshansdorf, Germany, Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, L’institut du Thorax, Nantes, France, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, Hospital Universitario La Fe, Valencia, Spain,

Abstract

A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.

Org: Servier Pharmaceuticals LLC,

Abstract

High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.

Org: Departments of Cutaneous Oncology and Immunology,

Abstract

Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.

Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Johns Hopkins Medicine, University of Chicago, Nanobiotix,

Abstract

Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.

Org: Melanoma Medical Oncology Department, Rheumatology and Clinical Immunology Section,

Abstract

First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.

Org: Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, Dana-Farber Cancer Institute, Boston, MA, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, Rogel Comprehensive Cancer Center, Ann Arbor, MI, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, Tom Baker Cancer Centre, University of Calgary, Alberta, Canada, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic, City of Hope Comprehensive Cancer Center, Duarte, CA, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Campus Biomedico, Roma, Italy, University Hospital of Parma, Fontevivo, Italy, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Vanderbilt University Medical Center, Nashville, TN, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA,

Abstract

A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).

Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Dermatology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, Greenville Health System, Abindgon,

Abstract

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,

Abstract

Long term results of phase 3 randomized study evaluating the addition of low dose nivolumab to palliative chemotherapy in head and neck cancer.

Org: P.D. Hinduja Hospital, Cancer Research and Statistic Foundation,

Abstract

First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.

Org: Barwon Health,

Abstract

Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO).

Org: Memorial Sloan Kettering Cancer Center, Adaptive Phage Therapeutics, Genitourinary Oncology Service, Weill Cornell Medical College University,

Abstract

eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).

Org: Head and Neck Medical Oncology Unit, Department of Oncology and Hemato-Oncology University of Milan,

Abstract

Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.

Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yale Cancer Center, Yale School of Medicine,

Abstract

First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104).

Org: National Cancer Center Hospital East, Kashiwa, Japan, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan,

Abstract

Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo.

Org: Peter O’Donnell Jr. School of Public Health,

Abstract

Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).

Org: Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan, JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Miyagi Cancer Center, Natori-Shi, Japan,

Abstract

Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy.

Org: University of Florida Department of Surgery, University of Florida College of Public Health and Health Professions, University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy,

Abstract

Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).

Org: Mayo Clinic, Duke University Medical Center, University of Chicago, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Dana-Farber Cancer Institute,

Abstract

Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).

Org: Department of Immunology, University of Pittsburgh,

Abstract

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC).

Org: Analysis Group Ltd.,

Abstract

Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.

Org: Fundación Cancer - Fuca, Hospital Sirio Libanes, Instituto Medico Rio IV, Centro de Investigación Clínica Bradford Hill, Erasto Gaertner Hospital,

Abstract

A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial.

Org: Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI,

Abstract

Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.

Org: 1440 Foundation,

Abstract

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

Org: Universitätsklinik Tübingen, Klinik für Urologie, University Medical Center of the Johannes Gutenberg-University Mainz, Hematology Oncology Practice Eppendorf (HOPE), University Cancer Center Hamburg (UCCH),

Abstract

A phase II study of nivolumab in patients with recurrent or metastatic carcinosarcomas.

Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Hospital, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, Samsung Medical Center,

Abstract

Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).

Org: Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,

Abstract

Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.

Org: Department of Head and Neck Tumor Radiotherapy, Department of Cardiology, Cardiac Prevention and Assessment Center,

Abstract

A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.

Org: Bucks, Nottingham University Hospitals NHS Trust, Churchill Hospital, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Trust,

Abstract

Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).

Org: University of California, San Diego (UCSD), Hematology/Oncology, Weill Cornell Medicine, Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center,

Abstract

Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.

Org: University of Navarra Clinic, Pamplona, Spain, START-CIOCC Hospital Universitario HM Sanchinarro, Madrid, Spain, Medical Oncology Department, Catalan Institute of Oncology (ICO), L'hospitalet De Llobregat, Spain, Department of Oncology/Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, Department of Hematology/Oncology, University of Wuerzburg, Wuerzburg, Germany,

Abstract

Triage of advanced cervical cancer through immunotherapy induction (TRACTION).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,

Abstract

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

Org: Melanoma Institute Australia,

Abstract

First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.

Org: Grampians Health, Austin Health and University of Melbourne, Olivia Newton-John Cancer Research Institute and La Trobe University, Murdoch Children's Research Institute,

Abstract

Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer.

Org: Frontier Science Foundation - Hellas, Hospital Virgen De La Salud, Hôpital Arnaud de Villeneuve, St. James's Hospital and Trinity College Dublin, Cancer Molecular Diagnostics,

Abstract

Phase II study of induction platinum doublet in combination with nivolumab followed by surgery or concurrent chemotherapy-nivolumab-radiation in unresectable stage IIIA-C non-small cell lung cancer (NSCLC).

Org: University of Kentucky College Department of Behavioral Health, The University of Kentucky Department of Human Health Sciences,

Abstract

First-line immunochemotherapy modulates peripheral immune landscape in advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC): Prediction of response to combination therapy.

Org: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, Simcere Medical Laboratory Science Co., Ltd.,, State Key Laboratory of Neurology and Oncology Drug Development,

Abstract

Financial impact of fixed-dose versus weight-based dosing approaches for pembrolizumab and nivolumab in the Oncology Care Model for The US Oncology Network (The Network).

Org: McKesson, The US Oncology Network, The Woodlands, TX,

Abstract

Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Toxicity of weight-based vs. flat dosing for immune checkpoint inhibitors in patients with low weight: Retrospective analysis from a tertiary care center.

Org: Chardon, OH, Cancer Informatics,

Abstract

The DIET study: A randomized controlled trial of a high fiber diet intervention (HFDI) in patients (pts) with melanoma receiving immune checkpoint blockade (ICB).

Org: Bionutrition Research Core,

Abstract

A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.

Org: H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Inc., Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

Org: The Netherlands Cancer Institute, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Cancer Center Amsterdam, University Medical Center Groningen, Leiden University Medical Center,

Abstract

Continuous intrathecal infusion of nivolumab in advanced melanoma with leptomeningeal disease.

Org: UFR Médecine Paris Nord, Neurosurgery Department, Assistance Publique hôpitaux de Paris, Beaujon Hospital, Mutimodal imaging lab (Biomaps) Université Paris Saclay/CEA/CNRS UMR9011/INSERM UMR1281,

Abstract

TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.

Org: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University,

Abstract

Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma.

Org: Novatim Immune Therapeutics (Zhejiang), Shanghai, China, Gracell Biotechnologies, Ltd., Fudan University, Shanghai, China,

Abstract

Altering the gut microbiome and TME in advanced liver cancers: A phase II study of nivolumab, tadalafil, and oral vancomycin in refractory HCC or liver-dominant metastatic CRC or PDAC.

Org: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,

Abstract

A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).

Org: Miami Cancer Institute, Baptist Health South Florida, Cleveland Clinic Lerner College of Medicine, Department of Internal Medicine, William Beaumont University Hospital, The University of North Carolina at Chapel Hill,

Abstract

Costs associated with novel first-line (1L) treatments in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) from a United States (US) Medicare and commercial payer perspective.

Org: EMD Serono Research & Development Institute, Evidera, Inc, The Healthcare Business of Merck KGaA, Darmstadt, Germany,

Abstract

Neoadjuvant nivolumab plus paclitaxel/cisplatin- chemo-radiotherapy (neo-NTP-CRT) followed by esophagectomy for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II study.

Org: Taiwan University Hospital,

Abstract

Comparison of ICI plus chemotherapy or ipilimumab plus nivolumab based therapy for patients with NSCLC with TPS (1-49%): TOPGAN2023-01.

Org: Hirosaki University, Japanese Foundation for Cancer Research, Kanazawa University Hospital, University of Yamanashi, The Jikei University Daisan Hospital,

Abstract

Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.

Org: Randwick, NSW, Australia, Central Clinical School, Califon, NJ, Scientia Clinical Research Ltd,

Abstract

NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi+nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC).

Org: Lifespan Health System, Brown University - Lifespan Cancer Institute, Cancer Center at Brown University, Brown University Department of Family Medicine,

Abstract

Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.

Org: A.C. Camargo Cancer Center, São Paulo, Brazil,

Abstract

First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.

Org: Melanoma Research Alliance,

Abstract

A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.

Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology Co. Ltd,

Abstract

With eyes on the future: Prospective evaluation of immune-related adverse events in patients with lung cancer.

Org: Hospital das Clinicas UFMG,

Abstract

The toxicity swimmer plot: A novel approach for evaluating patient-level toxicity following immune checkpoint inhibitor (ICI) therapy on the Checkmate 214 trial.

Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Georgetown-Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,

Abstract

Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

Org: Elekta - Kaiku Health, Antoni van Leeuwenhoek/Netherlands Cancer Institute (NKI), Sydney Medical School, Faculty of Medicine and Health Sciences, The University of Sydney,

Abstract

Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.

Org: Université Paris Cité, AP-HP Dermato-Oncology and CIC, Cancer Institute APHP, Aix-Marseille University, CEPCM, and CHU de La Timone APHM, Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron Hospital Medical Oncology Department, Leeds Institute of Medical Research at St. James’s, University of Leeds, Jonsson Comprehensive Cancer Center, University of California Los Angeles,

Abstract

Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.

Org: AZ Sint-Augustinus,

Abstract

Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

Org: Alberta, Canada, Sunnybrook Odette Cancer Centre,

Abstract

Retro TIMing: A multicentric retrospective analysis of immunotherapy timing in metastatic melanoma.

Org: Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, Unidade Local de Saúde de Santo António,

Abstract

Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy.

Org: Stanford Cancer Institute, Stanford Cancer Center,

Abstract

A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.

Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cleveland Clinic Taussig Cancer Instititute, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,

Abstract

The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.

Org: Inst for Clinical Evaluative Sci,

Abstract

A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.

Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,

Abstract

Overlapping and non-overlapping indications for checkpoint inhibitors in the US.

Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,

Abstract

Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).

Org: Vasgene Therapeutics, Inc, Newark, NJ, Orlando, FL,

Abstract

Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).

Org: Hackensack, NJ, University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center,

Abstract

Correlation between irAEs and treatment efficacy of anti-PD-1 single agent in patients with recurrent/metastatic head and neck squamous cell carcinoma: A monocentric real-world observational study.

Org: IOV – IRCCS,

Abstract

IL33-ST2 axis as a diagnostic and therapeutic biomarker in nivolumab therapy for advanced gastric cancer.

Org: Keio University Hospital,

Abstract

An update on SOC-1882: A phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.

Org: 2811 Wilshire Blvd., Suite 414,

Abstract

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.

Org: Johannes-Gutenberg University Clinic, Mainz, Germany, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile, Fundacion Arturo López Pérez, Providencia, Chile, Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland,

Abstract

Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.

Org: Gradyate School of Medicine, Department of Radiation Oncology and Image-Applied Therapy, Department of Therepeutic Oncology, Department of Clinical Trial Promotion, Clinical Trial Promotion Department,

Abstract

Combining nimotuzumab with PD-L1 inhibitors and chemotherapy to treat esophageal cancer: A retrospective study.

Org: First Affiliated Hospital of Guangdong Pharmaceutical University,

Abstract

Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.

Org: Division of General Thoracic Surgery, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery,

Abstract

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,

Abstract

Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.

Org: A.C. Camargo Cancer Center, Melanoma Institute Australia,

Abstract

Development of a novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with advanced melanoma undergoing treatment with combination immunotherapy.

Org: The Royal Marsden Hospital, The Royal Marsden Hospital NHS Foundation Trust, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,

Abstract

Heterogeneity of immune status in patient-derived malignant pleural effusion and ascites: Relationship to the ex-vivo efficacy of a HER2-targeted tri-specific antibody and a novel cytokine fusion protein.

Org: Nanjing JSIAMA Biopharmaceuticals Ltd, Nanjing JSIAMA Biopharmaceuticals Ltd., K2 Oncology Co. Ltd.,

Abstract

Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI).

Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Exploring the association of smoking status with clinical outcomes in patients with mPDAC treated on a clinical trial of maintenance niraparib plus immune checkpoint blockade.

Org: Penn Medicine Abramson Cancer Center,

Abstract

Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.

Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center, City of Hope Comprehensive Cancer Center, UCLA David Geffen School of Medicine,

Abstract

Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatimab.

Org: Georgetown University School of Medicine,

Abstract

A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.

Org: Samsung Medical Center, Sungkyunkwan University School of Medicine,

Abstract

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).

Org: University Hospital Jean Minjoz, Université de Franche-Comté, Inserm RIGHT, Besançon, CHU de Bordeaux,

Abstract

Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma.

Org: Curta Inc.,

Abstract

Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.

Org: Montgomery Regional Medical Campus,

Abstract

First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.

Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Division of Hematology and Medical Oncology, Mayo Clinic, Phoeniz, AZ,

Abstract

Cognitive symptoms in patients with cancer receiving PD-1/PD-L1 checkpoint inhibitors: Insights from a cross-sectional pilot study.

Org: University of Connecticut Internal Medicine Residency Program, University of Connecticut Health Center,

Abstract

Comparative efficacy of six programmed cell death protein-1 inhibitors in first-line treatment for advanced non-small cell lung cancer: A retrospective cohort study.

Org: Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,

Abstract

Comparison of checkpoint inhibitor–based regimens as first-line therapy in advanced hepatocellular carcinoma: A Frequentist Network meta-analysis of randomized clinical trials.

Org: Saint Mary's and Saint Clare's Hospital, Howard University Hospital, Reg Cancer Center at St Michael's Medical Center, St. Michael's Medical Ctr,

Abstract

Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309).

Org: University of Miami Bascom Palmer Eye Institute,

Abstract

Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.

Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,

Abstract

Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.

Org: Hospital do Servidor Público do Estado de São Paulo, Faculdade de Medicina de Barbacena FAME - FUNJOB, Centro de Oncologia do Paraná,

Abstract

A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).

Org: UPMC Hillman Cancer Center, Pittsburgh, PA, Replimune, Inc., Woburn, MA, Gustave Roussy and Paris-Saclay University,

Abstract

NCI MATCH (EAY131) arm Z1D: Retrospective evaluation of attributions of adverse events experienced on nivolumab in patients with MSI-high tumors.

Org: University of Maryland, Germantown, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Cancer Diagnosis Program, National Cancer Institute, Rockville, MD, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,

Abstract

The pan-cancer landscape of SMARCA4 and SMARCB1 alterations in a large cohort of Chinese patients.

Org: General Hospital of Central Theater Command, Suzhou, China,

Abstract

Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.

Org: Owkin France, Centre Leon Berad,

Abstract

Nivolumab monotherapy and associations in the treatment of advanced unresectable biliary tract cancer (BTC): A systematic review and meta-analysis.

Org: Canoas Health Office, Canoas, Brazil, Federal University of Pelotas, Belo Horizonte, Brazil,

Abstract

Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Org: Medical Oncology Society of Turkey, Health Science University Antalya Education and Research Hospital, Prof. Dr. Cemil Tascıoglu Hospital, Marmara University Pendik Research and Training Hospital, Necip Fazil City Hospital Department of Medical Oncology,

Abstract

Temozolomide and nivolumab in patients with refractory metastatic melanoma (MM).

Org: Vanderbilt University Medical Center,

Abstract

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,

Abstract

Intralesional nivolumab in oral potentially malignant disorders: A phase 1 pilot study on safety, tolerability, and preliminary efficacy.

Org: Department of Otorhinolaryngology-Head and Neck Surgery,

Abstract

Induction immunotherapy-based regimens followed by palliative CCRT may lead to conversion surgery in selected patients and boost survival for stage IV ESCC.

Org: National Taiwan University Hospital Yunlin Branch, Yunlin, Yun-lin Branch, Yunlin County,

Abstract

Interchangeability of anti-PD1 antibodies in patients (pts) with metastatic NSCLC.

Org: Moskovskii Mnogoprofilnyi Klinicheskii Tcentr Kommunarka Departamenta Zdravoohraneniia Goroda Moskvy, N.N. Blokhin National Medical Cancer Research Center of the Ministry of Healthcare of the Russian Federation, Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology, Clinical and Scientific Research Practical Oncological Center, Saint Petersburg Scientific Practical Center of Specialized Kinds of Medical Care,

Abstract

Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.

Org: Tianjin Lung Cancer Center, Charleston Oncology, Centre Hospitalier de l'Universite de Montreal, Institutul Oncologic Bucureşti Prof. Dr. Alexandru Trestioreanu, Azienda Unita Sanitaria Locale della Romagna,

Abstract

Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.

Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Abstract

Nivolumab combined with high dose multisite radiotherapy in previously untreated advanced melanoma (NIRVANA): A non-randomised, open-label, multicenter, phase 2 trial.

Org: Dermatology Department, Université Côte d'Azur, CHU de Nice, Nice, France,

Abstract

Cardiomyopathy among recipients of immune checkpoint inhibitor therapy: A prospective study.

Org: Division of Cardiovascular Imaging, St. Francis Hospital & Heart Center, DeMatteis Cardiovascular Institute of St. Francis Hospital, Cardio-Oncology Service, Cardiology Division,

Abstract

Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel after anti-PD-1 monotherapy.

Org: Case Western Reserve School of Medicine, Cleveland, OH, Case Western Reserve University School of Medicine,

Abstract

Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.

Org: Guys' and St. Thomas' NHS Foundation Trust, Southampton Experimental Cancer Medicine Centre, University of Southampton, Velindre Cancer Centre, Velindre University NHS Trust, Cancer Research UK & UCL Cancer Trials Centre, University College London, Department of Laboratory Medicine and Pathology, University of Washington,

Abstract

PD-1 inhibitors versus conventional therapies for adjuvant treatment of resected acral melanoma: A systematic review and meta-analysis.

Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Update on GALLANT: A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in previously treated sarcoma (NCT04535713).

Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center,

Abstract

Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.

Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Penn Medicine at Lancaster General Health, University of Pennsylvania, Abramson Cancer Center,

Abstract

Patterns of pembrolizumab use for recurrent cervical cancer.

Org: Columbia University Medical Center, Merck & Co., Inc., Herbert Irving Comprehensive Cancer Center,

Abstract

Quality of life outcomes in patients with resectable dedifferentiated liposarcoma treated with neoadjuvant immunotherapy.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,

Abstract

Org: Shaanxi Province,

Abstract

Effect of combinatorial immune checkpoint blockade on myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β, and interleukin-6: Biochemical implications in cardio-immuno-oncology.

Org: Division of Cardiology, Istituto Nazionale Tumori –IRCCS- Fondazione G. Pascale, Naples, Italy, IRCCS Fondazione G. Pascale, Napoli, Italy, Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy, Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella, Italy,

Clinical trial

A Phase II Study of Nivolumab in Combination With FOLFOX and Regorafenib in Patients With HER2-Negative Metastatic Esophagogastric Cancer

Status: Active (not recruiting), Estimated PCD: 2025-02-01

Clinical trial

Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a Phase 2 Study

Status: Completed, Estimated PCD: 2023-11-15

Clinical trial

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Status: Not yet recruiting, Estimated PCD: 2032-09-01

Clinical trial

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)

Status: Active (not recruiting), Estimated PCD: 2025-03-15

Clinical trial

Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2024-05-17

Clinical trial

An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Status: Completed, Estimated PCD: 2023-09-25

Clinical trial

Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab

Status: Recruiting, Estimated PCD: 2026-08-01

Clinical trial

Ambispective Observational Study of Muscle Invasive Urothelial Carcinoma Patients Treated With Adjuvant Nivolumab in France

Status: Not yet recruiting, Estimated PCD: 2028-05-01

Clinical trial

Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab Upon Achieving a (Confirmed) Complete or Partial Response in Patients With Irresectable Stage III or Metastatic Melanoma Treated With First-line Ipilimumab-nivolumab

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Phase II Study of Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in Patients With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Status: Completed, Estimated PCD: 2022-10-31

Clinical trial

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial

Status: Active (not recruiting), Estimated PCD: 2019-07-01

Clinical trial

Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Status: Terminated, Estimated PCD: 2019-07-02

Clinical trial

A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Status: Active (not recruiting), Estimated PCD: 2025-04-01

Clinical trial

ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma

Status: Terminated, Estimated PCD: 2020-11-05

Clinical trial

A Multi-Center Phase I/II Open Label Study to Evaluate Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimumab. (QUAD 01: Quadruple Therapy in Melanoma)

Status: Terminated, Estimated PCD: 2022-08-03

Clinical trial

Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

First-line Treatment for Grade 1-3A Follicular Lymphoma Using Opdivo (Nivolumab) Plus Rituximab: The 1st FLOR Study

Status: Active (not recruiting), Estimated PCD: 2022-05-11

Clinical trial

Improving Detection and Treatment of Locally Advanced Rectal Cancer by Dual Wavelength Quantitative Fluorescence Molecular Endoscopy Using Nivolumab-800CW and Durvalumab-680LT

Status: Not yet recruiting, Estimated PCD: 2025-03-01

Clinical trial

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Abstract

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).

Org: The University of Sydney, University of Pittsburgh Medical Center, Medical University of Vienna, Perlmutter Cancer Center at NYU Langone Health Medical Center, Elbe Klinikum Buxtehude,

Abstract

In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.

Org: Centre Léon Bérard, School of Medicine, Showa University, Centre François Baclesse, Groupe Hospitalier Diaconesses Croix Saint-Simon, Institut Claudius Regaud, IUCT-Oncopole, CRCT, lnserm, Toulouse, France,

Abstract

Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.

Org: University of Chicago Department of Surgery, University of Chicago Medical Center, Chicago, IL, Department of Medicine, University of Chicago, Department of Radiation and Cellular Oncology, Rush University Medical Center,

Abstract

Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial.

Org: Netherlands Cancer Institute (NKI-AVL), Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, The Netherlands Cancer Institute, University Medical Cancer Center Utrecht, Netherlands Cancer Institute,

Abstract

Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.

Org: City of Hope Comprehensive Cancer Center, CanSino Biologics, Flagstaff, Yale University School of Medicine, CTI BioPharma,

Abstract

Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.

Org: University of Leicester and Leicester University Hospitals, University of Southampton, Harry Perkins Institute of Medical Research, Perth, Australia, Liverpool, United Kingdom,

Abstract

Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

Org: Memorial Sloan Kettering Cancer Center, Niigata University Graduate School of Medical and Dental Sciences, ICON Research, Bristol Myers Squibb, West-German Cancer Center Essen,

Abstract

A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).

Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,

Abstract

Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).

Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,

Abstract

Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).

Org: UC San Diego Moores Cancer Center, National Cancer Institute/National Institutes of Health, Medical College of Wisconsin and WIN Consortium, Fred Hutchinson Cancer Center, Northwestern University,

Abstract

Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).

Org: START Madrid-CIOCC/University Hospital Sanchinarro, Early Drug Development Group, Division of Medical Oncology, National Cancer Center Singapore, Medical Oncology Department, CatalYm,

Abstract

ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.

Org: Medical Oncology Department, Institute of Biomedicine of Seville, Hospital Universitario y Politécnico La Fe, Son Espases University Hospital, University Hospital Virgen del Rocio,

Abstract

Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.

Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,

Abstract

Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).

Org: Helios Klinikum Berlin-Buch, Charité–Universitätsmedizin Berlin, Medizinische Fakultät “Carl Gustav Carus“ der TU Dresden, Universitätsklinikum Würzburg, Universität Heidelberg,

Abstract

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.

Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Henry Ford Cancer Institute, Detroit, MI, START San Antonio, San Antonio, TX, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, MUSC Hollings Cancer Center, Charleston, SC,

Abstract

The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.

Org: Melanoma Institute Australia, Mater and Royal North Shore Hospitals, Leiden University Medical Center, University Medical Center Utrecht, University Medical Center Groningen,

Abstract

Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).

Org: Division of Medical Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, UCL Cancer Center, University College London, London, United Kingdom, Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan,

Abstract

ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.

Org: Shizuoka Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Beijing Cancer Hospital, Department of Oncology, National Taiwan University Hospital,

Abstract

Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.

Org: Gwangju Institute of Science and Technology (GIST), prismCDX Co., Ltd, Asan Institute for Life Sciences, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,

Abstract

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.

Org: University of Texas MD Anderson Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University Duisburg-Essen, German Cancer Consortium, Instituto Oncológico Fundación Arturo López Pérez,

Abstract

Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.

Org: West German Cancer Center, University Hospital Essen, Jessa Hospital, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Pathology and Neuropathology,

Abstract

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

Org: Cross Cancer Institute, Assistance Publique Hôpitaux de Marseille (AP-HM), Fondazione IRCCS Istituto Nazionale Tumori, AZ Ospedaliera Villa Scassi, National Cancer Institute of Naples,

Abstract

Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).

Org: Memorial Sloan Kettering Cancer Center, Hartford Health Center Cancer Institute, Lehigh Valley Topper Cancer Institute, Weill Cornell Medical College University,

Abstract

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

Org: UPMC Hillman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Helen F. Graham Cancer Center and Research Institute, Newark, DE, University of Pittsburgh Department of Otolaryngology, University of Pittsburgh Medical Center,

Abstract

Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.

Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, University of Texas Southwestern Medical Center, Division of Digestive and Liver Diseases, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,

Abstract

Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).

Org: The Translational Genomics Research Institute (TGen), City of Hope Comprehensive Cancer Center, Centro de Cancer de Brasilia, Grupo Oncoclinicas, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,

Abstract

Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.

Org: Netherlands Cancer Institute, Melanoma Institute Australia, Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Netherlands Cancer Institute (NKI-AVL),

Abstract

Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018.

Org: Department of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke, Japan, Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan,

Abstract

Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.

Org: School of Medicine, Zhejiang University, Hangzhou, China, Yale University, New Haven, CTI BioPharma, Keck School of Medicine of the University of Southern California,

Abstract

Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.

Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,

Abstract

EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).

Org: University of Southern California Marshall School of Business, Vasgene Therapeutics, Inc, Rutgers University, Dana-Farber Cancer Institute, University of Colorado Cancer Center Anschutz Medical Campus,

Abstract

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.

Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Il-Yang Pharmaceuticals, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company,

Abstract

A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.

Org: Memorial Sloan Kettering Cancer Center, Stanford University Medical Center, Stanford, CA, Seoul National University Bundang Hospital, START Midwest, Grand Rapids, MI, Samsung Medical Center,

Abstract

Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.

Org: Frank H Netter MD School of Medicine, Dana-Farber Cancer Institute, Quinnipiac University, Dana-Farber Cancer Institute and Harvard Medical School,

Abstract

Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).

Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,

Abstract

Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.

Org: Melanoma Institute Australia, The Netherlands Cancer Institute, Amsterdam University Medical Centers, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The Christie NHS Foundation Trust,

Abstract

A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.

Org: Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe-Shi Chuo-Ku, Japan, Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe-Shi Chuo-Ku, HYOGO-KEN, Japan, Department of Head and Neck Oncology Division, Saitama Medical University International Medical Center, Hidaka-Shi, Japan, Department of Head and Neck Surgery, Miyagi Cancer Center, Sendai, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Osaka Med...,

Abstract

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).

Org: Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Illumina, Inc., Center for Biomedical Informatics & Information Technology, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,

Abstract

Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).

Org: Massachusetts General Hospital, Stanford Medical Center,

Abstract

Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.

Org: UPR "Chronotherapy, Cancers and Transplantation", Paris-Saclay University, Villejuif, France, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom, Department of Thoracic and Medical Oncology, Avicenne AP-HP, Université Sorbonne Paris Nord, Bobigny, France,

Abstract

Biology and performance of pre- and post-pembrolizumab (Pembro) vesical imaging–reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline.

Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Milano, Veracyte, Inc., IRCCS Ospedale San Raffaele, Radiology Unit,

Abstract

The study of immune-related adverse events in a community-based centre.

Org: BronxCare Health System, Bronx-Lebanon Hospital Center, BronxCare Mount Sinai Comprehensive Cancer Care,

Abstract

Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).

Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada,

Abstract

Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.

Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,

Abstract

Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.

Org: University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hämatologisch-Onkologische Praxis Eppendorf (HOPE) and University Cancer Center Hamburg (UCCH), Department of Internal Medicine IV, University Hospital Halle, Hematology Oncology Practice Eppendorf,

Abstract

The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.

Org: Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Barbara Ann Karmanos Cancer Institute, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center,

Abstract

TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.

Org: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, University of Wisconsin Carbone Cancer Center,

Abstract

Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.

Org: Perelman School of Medicine, University of Pennsylvania, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center,

Abstract

Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, Bristol Myers Squibb, Princeton, NJ, Exelixis, Inc., Alameda, CA, IQVIA, Amsterdam, Netherlands,

Abstract

KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, Eberhard Karls University of Tübingen, Tübingen, Germany, Icahn School of Medicine at Mount Sinai, New York, NY, Carolina Urologic Research Center, Myrtle Beach, SC,

Abstract

Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Society for Immunotherapy of Cancer, The Cancer Institute Hospital of JFCR, Tokyo, Japan, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Astellas Pharma Global Development,

Abstract

Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm.

Org: Saint John's Cancer Institute, Pacifica Neuroscience Institute, Pacific Neuroscience Institute and Saint John’s Cancer Institute at Providence Saint John’s Health Center, Saint John's Health Center,

Abstract

Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.

Org: Akershus University Hospital (Ahus), Lorenskog, Sørlandet Hospital, Kristiansand, St.Olav's University Hospital,

Abstract

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.

Org: West Cancer Center & Research Institute, University of Chicago, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital,

Abstract

A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.

Org: Hackensack University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Karmanos Cancer Institute, The Sarah Cannon Research Institute, Stephenson Cancer Center,

Abstract

Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC).

Org: TR supporting office, National Cancer Center Hospital East, Kashiwa, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, National Hospital Organization Osaka National Hospital, Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan,

Abstract

STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.

Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,

Abstract

SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Central University Hospital of Asturias, Hospital Juan Ramón Jiménez de Huelva, Hospital Clínic de Barcelona, IDIBAPS,

Abstract

A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.

Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,

Abstract

High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.

Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Utah, Huntsman Cancer Institute, Intermountain Medical Center,

Abstract

Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).

Org: Massachusetts General Hospital, UPMC Hillman Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Columbia University Irving Medical Center, New York, NY, USA,

Abstract

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Org: Vanderbilt-Ingram Cancer Center, University of Texas MD Anderson Cancer Center, University of Pennsylvania-Abramson Cancer Center, Cleveland Clinic Taussig Cancer Instititute, Massachusetts General Hospital Cancer Center and Harvard Medical School,

Abstract

Multisystem immune-related adverse events from dual agent immunotherapy use.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario Institute for Cancer Research, Toronto, ON, Canada, Oncotelic,

Abstract

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.

Org: Klinikum Rechts der Isar, Technische Universität München (TUM), Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,

Abstract

Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response.

Org: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).

Org: Tom Baker Cancer Centre, University of Calgary, BC Cancer Agency Vancouver Island Centre, University Hospital of Southern Denmark, University of Bari 'A. Moro',

Abstract

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.

Org: University of Calgary, Texas Oncology PA, Ipsen, Ontada, McMaster University and Juravinski Cancer Centre,

Abstract

Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort.

Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands, Netherlands Cancer Institute (Netherlands), Amsterdam, Netherlands, Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands, Hartwig Medical Foundation, Amsterdam, Netherlands, Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, Netherlands, Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands, Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands, Netherlands Cancer Institute, Amsterdam, Netherlands, Department of Medical Oncology, University Medical Cancer Center Utrecht, Utrecht, Netherlands, Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, Leiden University Medical Center, Leiden, Netherlands, Department of Medical Oncology, Erasmus Medical Center, Rotterdam, Netherlands, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands,

Abstract

Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).

Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,

Abstract

Melanomas lacking HLA class I expression and response to checkpoint inhibitor.

Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,

Abstract

Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.

Org: Roswell Park Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Institute, University Hospitals, Case Comprehensive Cancer Center, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Catholic Health Systems,

Abstract

CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).

Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,

Abstract

Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).

Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Data Sciences, Winship Cancer Institute of Emory University,

Abstract

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

Org: Washington University School of Medicine in St Louis, Natco Pharma, NATCO Pharma Limited,

Abstract

Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).

Org: University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, University of Pittsburgh Department of Otolaryngology,

Abstract

The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.

Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Moffitt Cancer Center, Tampa, FL,

Abstract

Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.

Org: Georgetown - Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Washington Cancer Institute/Georgetown-Lombardi Comprehensive Cancer Center, Medstar Franklin Square Medical Center, Georgetown Lombardi Comprehensive Cancer Center,

Abstract

Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).

Org: Moffitt Cancer Center, The Ohio State University - James Cancer Hospital and Solove Research Institute, Emory University School of Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,

Abstract

High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study.

Org: Università degli Studi di Milano, Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, University of Turin, Candiolo Cancer Institute-FPO, IRCCS,

Abstract

Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.

Org: New York University School of Medicine, Bristol Myers Squibb, Istituto Nazionale Tumori IRCCS Fondazione Pascale, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy,

Abstract

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.

Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,

Abstract

The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.

Org: Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, Applied Bioinformatics Laboratories, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Dermatology,

Abstract

Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).

Org: King's College London, Guy's and St. Thomas' NHS Foundation Trust, Guy's and St. Thomas' Hospital, Guys' and St. Thomas' NHS Foundation Trust,

Abstract

Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).

Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University – Purdue University Indianapolis, Barbara Ann Karmanos Cancer Institute, Indiana University Simon Comprehensive Cancer Center,

Abstract

Serum soluble MAdCAM-1: A new biomarker for cancer immunotherapy.

Org: Gustave Roussy Cancer Campus, Centre Léon Bérard, Department of Medicine and Surgery, University of Parma, Parma, Italy, University of Parma, Medical Oncology Group,

Abstract

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).

Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, UC San Diego Moores Cancer Center, University of Kansas Medical Center, Department of Biostatistics & Data Science, Loma Linda University Department of Radiation Technology,

Abstract

A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.

Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,

Abstract

Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.

Org: Bristol Myers Squibb, Mayo Clinic, Charite Universitats Medizin, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Roswell Park Comprehensive Cancer Center,

Abstract

Implementation of a streamlined prior authorization process to improve cancer care delivery.

Org: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY,

Abstract

Molecular subtypes from comprehensive clustering from multi-omics dataset to predict the therapeutic efficacy of immunotherapeutic agent-based treatments in advanced hepatocellular carcinoma.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, CHA University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Medical Oncology Group,

Abstract

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.

Org: Imperial College London, MRC Clinical Trials Unit UCL, Christie Hospital NHS Foundation Trust and the University of Manchester, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, University of Liverpool,

Abstract

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.

Org: Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Johannes-Gutenberg University Clinic, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Fundacion Arturo López Pérez,

Abstract

Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.

Org: The First Hospital of China Medical University, Shenyang, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of China Medical University,

Abstract

Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.

Org: Faculty of Biology, Technion-Israel Institute of Technology, Carelon Digital Platforms,

Abstract

Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.

Org: Yale University School of Medicine, Ocean Genomics, Yale University Dept of Pathology, Yale School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT,

Abstract

Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.

Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine in St Louis,

Abstract

Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.

Org: National Cancer Institute, Vilnius, Lithuania, National Institutes of Health Division of Occupational Health and Safety, Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI,

Abstract

Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Yale University,

Abstract

Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).

Org: City of Hope Comprehensive Cancer Center, Quantitative Medicine and Systems Biology Division, Translational Genomics Research Institute (TGen North), Integrated Cancer Genomics Division, Yale University School of Medicine,

Abstract

A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.

Org: Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, McGill University Health Centre, Montréal, QC, Canada, Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), Sherbrooke, QC, Canada,

Abstract

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.

Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center and Weill Cornell College of Medicine,

Abstract

CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.

Org: City of Hope National Medical Center, John Wayne Cancer Institute, University of Washington and Fred Hutchinson Cancer Research Centre, CARTI Cancer Center, ImaginAb,

Abstract

A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.

Org: The Institute of Cancer Research, The Royal Marsden Hospital, University of California Irvine, UPMC Hillman Cancer Center, Sarah Cannon Cancer Institute HCA Midwest Health,

Abstract

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, Columbia University Irving Medical Center, New York, NY, USA, Yale School of Public Health,

Abstract

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.

Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Cancer Center,

Abstract

Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.

Org: Mayo Clinic, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,

Abstract

Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis.

Org: University of Kentucky, Lexington, KY,

Abstract

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).

Org: James P. Wilmot Cancer Center/URMC - JPWCC, Memorial Sloan Kettering Cancer Center,

Abstract

A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.

Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,

Abstract

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.

Org: University of Southern California Norris Comprehensive Cancer Center, MD Anderson Cancer Center, University Hospitals Gasthuisberg/Leuven and KU Leuven, Hospital Universitario Virgen del Rocio, Westmead Hospital,

Abstract

Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.

Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, Johns Hopkins University Department of Rheumatology, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD,

Abstract

STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Org: Mass General Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Arcus Biosciences, Gilead Sciences, Inc., Memorial Sloan Kettering Cancer Center,

Abstract

Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.

Org: Division of Surgical Oncology, Department of Surgery, The Ohio State University, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, The Netherlands Cancer Institute,

Abstract

Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma.

Org: Imperial College, Imperial College London, Imperial College, St Mary's Campus, Imperial College Healthcare NHS Trust, Barts and The London HPB Centre,

Abstract

Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.

Org: FibroFighters Foundation, River Forest, IL, Rush University Medical Center, Chicago, IL, University of Zürich,

Abstract

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.

Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Moffitt Cancer Center, Johns Hopkins Medicine, Nanobiotix,

Abstract

Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.

Org: King's College London, ISA Pharmaceuticals B.V., Gustave Roussy Département d'Organisation du Parcours Patient, Centre Leon Bérard, H. Lee Moffitt Cancer Center & Research Institute,

Abstract

The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB).

Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas at MD Anderson Cancer Center,

Abstract

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.

Org: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, The Clatterbridge Cancer Centre and University of Liverpool, Liverpool, United Kingdom, Intermountain Medical Center, Murray, UT, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA,

Abstract

Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08).

Org: St. Marianna University School of Medicine, Osaki Citizen Hospital, Sakai City Medical Center, Teine Keijinkai Hospital, Ikeda City Hospital,

Abstract

Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.

Org: Hospital Israelita Albert Einstein,

Abstract

FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO.

Abstract

A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.

Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Samsung Medical Center, Seoul, South Korea, Samsung Medical Center, Gangnam-Gu, South Korea,

Abstract

Economic evaluation for the US of relatlimab and nivolumab (RELA+NIVO) versus nivolumab (NIVO) monotherapy in untreated advanced melanoma.

Org: University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,

Abstract

Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).

Org: MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, U T MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.

Org: University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA, Washington University School of Medicine in St Louis, St. Louis, MO, Department of Immunology and Oncology, Clínica Universidad de Navarra,

Abstract

Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Abstract

Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.

Org: The Clatterbridge Cancer Centre and University of Liverpool, The Institute of Cancer Research, Replimune, Department of Oncology, University of Oxford,

Abstract

Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.

Org: City of Hope Comprehensive Cancer Center, Sarcoma Oncology Research Center, Santa Monica, CA, Aveni Foundation, Sarcoma Oncology Center,

Abstract

Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.

Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, City of Hope Comprehensive Cancer Center, Duarte, CA, Aveni Foundation,

Abstract

Factors associated with myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Org: Bristol Myers Squibb, Mayo Clinic,

Abstract

First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, UC Davis Comprehensive Cancer Center, Sacramento, CA, Dana-Farber Cancer Institute, Department of Medical Oncology, University of California San Diego,

Abstract

Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.

Org: Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, UMass Chan Medical School, Shrewsbury, MA,

Abstract

Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).

Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas - M. D. Anderson Cancer Center, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center,

Abstract

Efficacy-effectiveness gap with immune checkpoint inhibitors in solid cancers: A population based cohort study.

Org: University of Manitoba, CancerCare Manitoba,

Abstract

Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.

Org: Kurume University Hospital, Kanagawa Cancer Center, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, National Hospital Organization Kinki-Chuo Medical Center, Osaka International Cancer Institute, Osaka, Japan,

Abstract

Safety of checkpoint inhibitors in older patients with genitourinary cancers.

Org: University of Florida/UF Health Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,

Abstract

Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, IU Simon Comprehensive Cancer Center, Indianapolis, IN, Innovative Immunotherapy Alliance,

Abstract

ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

Org: Duke Cancer Institute, Duke University Medical Center, Sarcoma Oncology Center, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Royal Marsden Hospital and Institute of Cancer Research,

Abstract

Immunotherapy and radiotherapy in metastatic uveal melanoma: Results from a single institute study.

Org: Houston Methodist Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Retina Consultants of Texas,

Abstract

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.

Org: Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI, Nihon Medi-Physics, Hospital Sírio-Libanês,

Abstract

Incidence of venous thromboembolism with immune checkpoint inhibitors in a community setting: A single-center retrospective study.

Org: Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Cancer and Wellness Center,

Abstract

Immune checkpoint inhibition in locally advanced rectal adenocarcinoma at Mayo Clinic.

Org: Mayo Clinic, Jacksonville, FL,

Abstract

Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06).

Org: Soonchunhyang University Bucheon Hospital, Pusan National University Yangsan Hospital, Ulsan University Hospital, College of Medicine, Chungbuk National University, Seoul St. Mary's Hospital,

Abstract

Immunotherapy-related toxicities: A retrospective analysis of barriers to prompt detection and initiation of treatment in renal cell carcinoma.

Org: TCU School of Medicine, UTSW Harold C Simmons Comprehensive Cancer Center,

Abstract

[18F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma.

Org: The Netherlands Cancer Institute (NKI), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Division of Medical Oncology, Netherlands Cancer Institute, Department of Head and Neck Surgical Oncology, Netherlands Cancer Institute (NKI-AVL),

Abstract

The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.

Org: Princess Margaret Cancer Centre, ICES, Ontario Health (Cancer Care Ontario), Princess Margaret - University Health Network, University Health Network,

Abstract

Toxicity and outcomes of ipilimumab plus nivolumab in patients 80 years and older.

Org: Mayo Clinic in Arizona, Phoenix Tissue Repair, Azidus Brasil, Mayo Clinic Arizona, Phoenix, AZ, Scottsdale,

Abstract

The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre.

Org: Hull University Teaching Hospitals NHS Trust, University of Leeds, Royal Cornwall Hospital NHS Trust,

Abstract

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Org: Mayo Clinic, Alliance Statistics and Data Management Center, Mayo Clinic Arizona, Phoenix, AZ, University of Pittsburgh Medical Center, Johns Hopkins Medicine,

Abstract

A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.

Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,

Abstract

Real-world experience of checkpoint inhibitors across India: CRSF 2020-01.

Org: Max Super Speciality Hospital, Aster Mims Calicut, Malabar Cancer Centre, Regency Hospital, Bombay Hospital,

Abstract

A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.

Org: Melanoma Institute Australia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, Chris O'Brien Lifehouse, The University of Sydney, The Mater Hospital Sydney,

Abstract

A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.

Org: University of Tennessee Medical Center at Knoxville, Orlando Health Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, St. John's Cancer Institute, Santa Monica, CA,

Abstract

The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.

Org: Netherlands Cancer Institute, Division of Psychosocial Oncology and Epidemiology, Core Facility Molecular Pathology and Biobanking, Melanoma Institute Australia, The University of Sydney,

Abstract

Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.

Org: Beaumont RCSI Cancer Center, Vanderbilt University Medical Center, ConcertAI, Bristol Myers Squibb, Bristol-Myers Squibb,

Abstract

FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.

Org: A.C. Camargo Cancer Center, São Paulo, Brazil, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil, Beneficencia Portuguesa, AC Camargo Cancer Center,

Abstract

Long-term follow-up results of ipilimumab and nivolumab for the treatment of mismatch repair deficient locally advanced rectal cancer.

Org: University of Wisconsin Carbone Cancer Center, Madison, WI,

Abstract

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

Org: University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Partner Site Munich, Partner Site Essen,

Abstract

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

Org: University Medical Center Utrecht, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, VU University Medical Center, Isala Oncology Center, University Medical Center of Utrecht,

Abstract

A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).

Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden,

Abstract

Reveal irAE by analysis of 197,921 claim-based prescriptions.

Org: AESOP Technology Inc.,

Abstract

Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI).

Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,

Abstract

The association between body mass index and immune checkpoint inhibitors outcomes in melanoma: Results from real-world data.

Org: MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Seidman Cancer Center,

Abstract

Impact of antibiotics on survival outcomes and risk of gastritis/colitis in patients with advanced-stage melanoma receiving anti-PD-1 therapy.

Org: University of Wisconsin Health, University of Wisconsin-Madison Carbone Cancer Center, University of Wisconsin, Madison, University of Wisconsin - Carbone Cancer Center,

Abstract

Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.

Org: Mount Vernon Cancer Center, Northwood, United Kingdom, Christie NHS Foundation Trust, Manchester, United Kingdom, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Royal Preston Hospital,

Abstract

Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,

Abstract

Nivolumab usage patterns combined with TKI for mRCC: Financial toxicity and clinical outcomes from self-paying patients in India—Is low dose an option when access is limited?

Org: Christian Medical College & Hospital Vellore, Christian Medical College Vellore, Department of Uro-Oncology, Chongqing University Cancer Hospital, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,

Abstract

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).

Org: Department of Medical Oncology, University of California San Diego, San Diego, CA, St. Martin’s University, Lacey, WA, Northwestern, Chicago, IL, University of Chicago Department of Medicine, Chicago, IL, University of Kansas Cancer Center, Westwood, KS, University of Pittsburgh Medical Center Oncology Group, Beaver, PA, University of Florida Health Cancer Center, Gainesville, FL, University of Chicago, Chicago, IL, Fred Hutchinson Cancer Research Center, Seattle, WA, SWOG Data Operations Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA, National Cancer Institute, Bethesda, MD, National Cancer Institute/National Institutes of Health, Bethesda, MD, OHSU Knight Cancer Institute, Portland, OR, Oregon Health and Science University, Departments of Medicine and Pediatrics/ Kn, Portland, OR, Medical College of Wisconsin and WIN Consortium, Milwaukee, WI,

Abstract

Implementation of the novel use of an objective scoring rubric to reduce utilization of inpatient non-formulary chemotherapy.

Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Health System, Mount Sina Health System,

Abstract

A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.

Org: Hoag Family Cancer Institute and University of Southern California, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Buzzard Pharmaceuticals AB, Buzzard Pharmaceuticals,

Abstract

Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.

Org: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, MD,

Abstract

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.

Org: GKT School of Medicine, King's College London, Curenetics Ltd, Imperial College London, School of Physics, Engineering & Computer Science,

Abstract

Replacement of anti-PD-1 drugs with prolgolimab during treatment, safety and efficacy.

Org: AV Medical Group, Saint-Petersburg, Russian Federation, LLC Oncological Research Center, NII of Oncology name after Petrov,

Abstract

Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer.

Org: Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Mount Auburn Hospital, Harvard Medical School, Lahey Hospital and Medical Center, Burlington, MA,

Abstract

Hemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: A pharmacovigilance study from FDA Database.

Org: Rochester General Hospital, Rochester, NY, Patan Academy of Health Sciences, Kathmandu, Nepal, Kathmandu, Nepal, University at Buffalo Jacobs School of Medicine and Biomedical Sciences,

Abstract

Measuring time toxicity of systemic therapies for advanced esophageal and gastric cancers.

Org: Oregon Health & Science University, Medical Oncology Group, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Knight Cancer Institute,

Abstract

Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067.

Org: Dana-Farber Cancer Institute, Veneto Institute of Oncology IOV–IRCCS, University of Colorado Cancer Center, Aix-Marseille University CHU Timone, Maria Skłodowska-Curie National Institute of Oncology Center,

Abstract

Real world data on immunotherapeutic outcomes in solid tumours.

Org: The Brunei Cancer Center, The Brunei Cancer Centre,

Abstract

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck.

Org: UC San Diego Moores Cancer Center, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Hoag Memor Hosp, Hoag Family Cancer Institute and University of Southern California,

Abstract

Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela.

Org: Centro Medico Docente La Trinidad, Caracas, Venezuela (Bolivarian Republic of), Beth Israel Deaconess Medical Center, Boston, MA, Advocate Aurora Health, Chicago, IL, Centro Medico Docente la Trinidad, Caracas, Miranda, Venezuela (Bolivarian Republic of),

Abstract

Extracorporeal removal of soluble tumor necrosis factor receptors for the treatment of advanced refractory solid tumors.

Org: Immunicom, Inc., Sheba Medical Center, Or-Yeuda, Rabin Medical Center Davidoff Cancer Centre, Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Teva Pharmaceuticals,

Abstract

A functional immuno-oncology (IO) assay to assess patient response to immunotherapeutics in metastatic disease.

Org: Xilis, Inc., Xilis Inc., Xilis,

Abstract

Safety and tolerability of immune checkpoint inhibitor (CPI) use in advanced hepatocellular carcinoma (aHCC) with Child-Pugh (CP) class B and C.

Org: UC Irvine, University of California Irvine, UCI Health,

Abstract

Adrenal insufficiency in patients on immune checkpoint inhibitors: An All of Us Data study.

Org: Harlem Hospital Center, New York Oncology Hematology PC,

Abstract

Retreatment with nivolumab and ipilimumab with or without chemotherapy in patients with metastatic non-small cell lung cancer after progression on immune checkpoint inhibitor therapy.

Org: Lausanne University Hospital, Geneva University Hospitals,

Abstract

Evaluating novel imaging-based mathematical modeling prediction of immunotherapy response by individual melanoma brain metastasis and patient prognosis.

Org: University of Texas MD Anderson Cancer Center, Houston, TX, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Queensland Health,

Abstract

Value of Patlak-Ki from ultra-high sensitivity dynamic total body [18F]FDG PET/CT for evaluation of treatment response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer (LA-NSCLC) patients.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, United-Imaging Healthcare, Molecular Imaging Business Unit,

Abstract

Predicting non-small cell lung cancer response to immune checkpoint inhibitors with machine learning based on heterogeneous biomarkers.

Org: INRIA, Sophia Antipolis, Centre Antoine Lacassagne, Center hospitalier Princesse-Grace, Univ Rouen Normandie,

Abstract

Real-world efficacy of nivolumab in Peruvian patients with advanced melanoma.

Org: Ninth of July University (UNINOVE), Brazil, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, INEN Lima, Surquillo, Peru, Oncosalud, Lima, Peru, Universidad Nacional Federico Villareal, Lima, Peru,

Abstract

Profile of toxicities and quality of life in long-term survivors treated with immunotherapy: A prospective cross sectional trial.

Org: University of Brescia, ASST Spedali Civili - Brescia, University Hospital of Parma, University of Pisa, Pisa, Italy, ATC Innovation Lab,

Abstract

Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.

Org: HIA SAINTE ANNE, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,

Abstract

Atypical new metastatic sites after immunotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M H&NSCC).

Org: Inova Schar Cancer Institute, Inova Fairfax Hospital,

Abstract

Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.

Org: National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Cleveland Clinic Taussig Cancer Instititute, Medical College of Wisconsin, NYU Langone Laura and Isaac Perlmutter Cancer Center,

Abstract

Translational analysis of combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer.

Org: Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center,

Abstract

Incidence and outcomes of immune-related adverse events after immune checkpoint inhibitors in patients with Hodgkin lymphoma.

Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,

Abstract

Patterns of care delivery and outcomes in patients with melanoma brain metastases treated with ipilimumab/nivolumab.

Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke Cancer Institute, Duke Medical Center, Department of Radiation Oncology, Duke University Medical Center, Durham, NC,

Abstract

Efficacy of checkpoint inhibitors in hospitalized patients with cancer.

Org: Rutgers Health Community Medical Center, Monmouth Medical Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,

Abstract

Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab.

Org: Maria Sklodowska-Curie National Research Institute of Oncology, Heliodor Swiecicki Clinical Hospital, Greater Poland Cancer Centre, Mossakowski Medical Research Centre, Polish Academy of Sciences,

Abstract

Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?

Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA, PainReform,

Abstract

The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan Bio Therapeutics, Yun-lin Branch,

Abstract

Immune therapy related adverse events in metastatic non-small cell lung carcinoma patients at a rural academic center.

Org: Brody School of Medicine at East Carolina University, ECU Health,

Abstract

Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathologic study.

Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Kansas City, MO, KSQ Therapeutics, Cambridge, MA,

Abstract

Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.

Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,

Abstract

Sarcopenia vs body mass index (BMI) as a prognostic biomarker in patients with metastatic clear cell renal cell carcinoma (mCCRCC) in the era of first line immune checkpoint inhibitors (ICIs).

Org: University of Washington School of Medicine, Vanderbilt University Medical Center, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Emory University, Atlanta, GA, USA,

Abstract

Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.

Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,

Abstract

Efficacy and safety of encorafenib-based regimens in colorectal cancer: A systematic review of clinical trials.

Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, St. Michael's Medical Ctr, Reg Cancer Ctr At St Michael's Medical Ctr,

Abstract

Evaluation of immune related adverse events following extended interval dosing of immune checkpoint inhibitors.

Org: Gundersen Health System, La Crosse, WI, Gundersen Clinic Ltd,

Abstract

How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.

Org: Gilead Sciences, Inc., Foster City, CA, Certara, Inc., Princeton, NJ, Gilead Sciences Inc.,

Abstract

Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer.

Org: University of Michigan, Fred Hutchinson Cancer Research Center, Beaumont Health, University of Michigan Health Management Research Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,

Abstract

AI-based pathologic biomarker for pathologic downstaging in patients with muscle-invasive bladder cancer undergoing cystectomy after neoadjuvant nivolumab, gemcitabine, and cisplatin: BLAAST-1 Trial.

Org: Valar Labs, Inc., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Huntsman Cancer Institute, Hunstman Cancer Institute at the University of Utah,

Abstract

Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data.

Org: Pfizer Inc., London, United Kingdom, Kirkland, QC, Canada, Pfizer, Inc., Cambridge, MA, Pfizer,

Abstract

Incidence of immune checkpoint inhibitor induced myocarditis in patients with mesothelioma from a regional tertiary cancer centre covering a patient population of 2.6 million.

Org: Clatterbridge Cancer Centre NHS FT, Liverpool Hospital Anatomical Pathology, Wirral,

Abstract

Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.

Org: National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark, Technical University of Denmark – DTU, HEALTH TECH, Department of Health Technology, Lyngby, Denmark, National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark, Center for Cancer Immune Therapy-CCIT Herlev Hospital (Denmark), Herlev, Denmark, Evaxion Biotech, Hoersholm, Denmark,

Abstract

Nivolumab treatment of NSCLC patients in clinical practice in Greater Poland: Long term survival analysis.

Org: E.J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Department of Thoracic Surgery, Poznan University of Medical Sciences,

Abstract

A phase I/II trial of NOX66 in combination with nivolumab in patients (pts) with advanced cancer.

Org: University of Sydney Medical School, Blacktown Cancer and Haematology Centre, Sydney Adventist Hospital, Western Sydney University, Liverpool Hospital Anatomical Pathology,

Abstract

CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.

Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Charles Gairdner Hospital, Harry Perkins Institute for Medical Research, University of Western Australia & Linear Clinical Research, Melbourne, Australia,

Abstract

Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort.

Org: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Oncology, Cancer center, Zhongshan Hospital, Fudan University, Shanghai, China,

Abstract

Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.

Org: Federal University of Minas Gerais - UFMG, Princess Margaret Hospital, Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto,

Abstract

Nivolumab as second-line treatment of patients with metastatic renal cell carcinoma with high or normal fibrinogen levels: A prospective, cohort study.

Org: Bureau for Cancer Research - BUCARE, City Clinical Cancer Hospital No. 1, Institute of Oncology Angel H Roffo, Hadassah Medical Moscow, State Budgetary Healthcare Institution Saint-Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care,

Abstract

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.

Org: Université Paris Cité, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, Hôpital Bichat Claude Bernard, AP-HP.Nord, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Abstract

COVID-19 induced remission of biliary and renal cell carcinomas.

Org: University of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA,

Abstract

Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).

Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,

Abstract

Dissecting the relationship between ethnicity and response to checkpoint inhibitors in patients with acral melanoma.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,

Abstract

Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase 2 IKF-S627/RAMOS trial of the AIO.

Org: Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, Munich, Germany, Munich, Germany, Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt Am Main, Germany, Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, Städtisches Klinikum Dresden, IV. Medical Clinic, Dresden, Germany, CaritasKlinikum Saarbrücken, Klinik für Hämatologie und Onkologie, Saarbrücken, Germany,

Abstract

Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.

Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,

Abstract

Five-year survival outcomes in patients with melanoma with complete response to immunotherapy who discontinue therapy.

Org: University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Abramson Cancer Center, University of Pennsylvania,

Abstract

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.

Org: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Biotherapy Center,

Abstract

A preliminary analysis of integrating thymosin α1 into concurrent chemoradiotherapy and consolidative immunotherapy.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil.

Org: CAPESESP,

Abstract

Association between immunotherapy and hypothyroidism in a Latin American population: An analytical study of cases and controls from 2019 to 2023.

Org: Hospital Fundación Santa Fe de Bogotá, Hospital Universitario Fundación Santa Fe de Bogotá,

Abstract

Impact of BAP1 mutational status on immunotherapy outcomes in advanced malignant pleural mesothelioma: A single institution experience.

Abstract

Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC).

Org: Abramson Cancer Center at the University of Pennsylvania, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Medical College of Wisconsin, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Cedars-Sinai Medical Center,

Abstract

Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.

Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Careggi University Hospital, Department of Experimental and Clinical Medicine - Careggi University Hospital, Largo Brambilla, University of Florence, AOUC,

Abstract

Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).

Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,

Abstract

Immune checkpoint inhibitors in cutaneous squamous cell carcinoma: A systematic review of clinical trials.

Org: BronxCare Health System, New York Medical College - Saint Michael's Medical Center, Saint Mary's and Saint Clare's Hospital, Mercy Hospital Fort Smith, Arkansas College of Osteopathic Medicine,

Abstract

Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.

Org: Hôpital Européen Georges-Pompidou, Paris, Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, University Hospital 12 de Octubre, LMU Munich,

Abstract

“Interchangeability” of anti-PD1 antibodies in patients (pts) with metastatic melanoma (mM).

Org: Moskovskii Mnogoprofilnyi Klinicheskii Tcentr "Kommunarka" Departamenta Zdravoohraneniia Goroda Moskvy, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, N.N. Blokhin NMRCO, N.N. Petrov Institute of Oncology, Kommunarka Moscow City Clinical Center,

Abstract

Patients characteristics, treatment patterns and clinical outcomes in patients with head and neck squamous cell carcinoma (aHNSCC) receiving immunotherapy in advanced setting: Retrospective cohort analysis of real-world data in Spain.

Org: Servicio de Oncología Médica, Hospital Universitario de Jaén, Jaén, Spain, Servicio de Farmacia Hospitalaria,

Abstract

Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.

Org: Mayo Clinic Florida, Mayo Clinic,

Abstract

Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer.

Org: University Hospitals Cleveland Medical Center, Cleveland, OH, Case Western Reserve University School of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center,

Abstract

Eosinophilia in patients with melanoma under treatment with immune checkpoint inhibitor-based regimens.

Org: First Department of Internal Medicine, Hematology and Oncology Unit, Athens, Greece, First Department of Internal Medicine, Laiko Hospital, Athens, Greece, First Department of Internal Medicine, Laiko Hospital, Athens, Greece, Athens, Greece, First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece,

Abstract

Systemic inflammation markers ratio in heavily pretreated NSCLC patients treated with nivolumab.

Org: Clinical Hospital Centre Zagreb, Zagreb, Croatia,

Abstract

Efficacy of immunotherapy in MSI metastatic colorectal cancer patients: A Real-World Italian multicentric retrospective study (Colon-MSI Study).

Org: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliero-Universitaria Pisana, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience.

Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SOLTI Cancer Research Group, Hospital Vall d'Hebron,

Abstract

Retrospective analysis of NUT carcinoma: The Northwestern experience.

Org: Northwestern Medicine Cancer Center Warrenville, Northwestern University-Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,

Abstract

Relationship of adverse events after combined immunotherapy and treatment outcomes in patients with advanced melanoma: A multicenter experience in Poland.

Org: The Maria Skłodowska-Curie National Research Institute of Oncology, Kraków Branch, Oncology Center - Prof Franciszek Lukaszczyk Memorial Hospital, Frederic Chopin Provincial Hospital No.1, Specialist Oncological Hospital NU-MED LCC-Chemotherapy Subward, Medical University of Lodz, Lodz, Poland,

Product

nivolumab + hypofractionated multisite radiotherapy

Abstract

Efficacy of nivolumab and relatlimab-rmbw in patients with advanced melanoma who were previously treated with PD-1 inhibitor: Real world experience.

Org: Inova Schar Cancer Institute,

Abstract

Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.

Org: Arnie Charbonneau Cancer Research Institute, University of Calgary, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Alberta, Tom Baker Cancer Centre,

Abstract

CAROLINE study: Incidence and characterization of melanoma in French Polynesia.

Org: Gustave Roussy Institute, Hopital Europeean Georges Pompidou, Universite Paris Cite, CHU Poitiers - Jean Bernard Hôpital, Centre Hospitalier de Polynésie Francaise - Site du Taaone-Pirae,

Abstract

Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.

Org: FibroFighters Foundation, Rush University Medical Center, University of Zürich, Columbia University - Mailman School of Public Health, UPMC Health Plan,

Abstract

Outcomes of stage IV non-small cell lung cancer patients after failure of platinum-based chemotherapy in clinical trials and real-world settings: A literature review.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute Singapore, Real Chemistry, Inc., Novocure Inc., NovoCure,

Abstract

Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study.

Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Health Sciences, University of Florence, Florence, Italy, Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy, Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy,

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10495

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20180

Abstract

https://www.abstractsonline.com/pp8/#!/20272/presentation/11424

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20466

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20191

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20340